Takeda Pharmaceutical has completed an acquisition of Shire for $62bn.
The acquisition was approved by the shareholders of Takeda in December 2018. It is expected to strengthen Takeda’s presence in Japan and the US.
Takeda is a Japan-based pharmaceutical company with a presence in 70 countries worldwide, while Shire is a US-based biotechnology company focused on developing biologic therapies for patients with rare diseases.
Eli Lilly has entered a definitive agreement to acquire Loxo Oncology for $8bn.
The acquisition is expected to strengthen Eli Lilly’s cancer treatment portfolio.
The deal is expected to be completed by Q1 2019, subject to customary closing conditions and regulatory approvals.
Based in the US, Eli Lilly is engaged in the development and sale of pharmaceutical products, while Loxo Oncology is focused on the development of medicines for patients with genetically defined cancers.
Claudio Bidco has completed an acquisition of MedCan Pharma.
The combined company will work on the development of medicated chewing gum and other oral delivery systems and form a strong platform for the commercial development of medicinal cannabinoid products.
Based in Denmark, MedCan Pharma is focused on the development of innovative cannabinoid products, while Claudio Bidco is a producer of medicated chewing gum.
Kashiv Pharma has announced plans to acquire Adello Biologics to form a new company named Kashiv BioSciences.
The new company’s product portfolio will include drug delivery systems featuring delayed-release technology and gastric retention systems, and a pipeline of seven development products.
Adello Biologics is a biotechnology company engaged in the development of biosimilars in the field of oncology and immunology, while Kashiv Pharma is a pharmaceutical research and development company.
Both the companies involved in the acquisition are based in the US.
Aphria has completed the acquisition of CC Pharma, a Germany-based pharmaceutical company and distributor of medical cannabis.
Shareholders of CC Pharma have received a cash payment of €18.92m ($21.65m) as part of the acquisition. CC Pharma is also entitled to receive up to €23.5m ($26.89m) in performance milestones.
The acquisition will enhance Aphria’s cannabis operations in Germany.